Statistics from Altmetric.com
Virbac has launched the first injectable solution for the targeted treatment of canine mast cell tumours (MCTs).
Stelfonta is licensed in dogs for the treatment of non-resectable, non-metastatic subcutaneous MCTs located at or distal to the elbow or the hock; and non-resectable, non-metastatic cutaneous MCTs, where tumours are less than 8 cm3 in volume and accessible to intratumoural injection.
The solution contains tigilanol tiglate – a compound extracted from the seed of Fontainea picrosperma, commonly known as the …
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.